Meagan O’Brien
Company: Regeneron
Job title: Senior Medical Director
Seminars:
Joint Q&A Session 12:30 pm
Have the speakers answer your questionsRead more
day: Day One
CRISPR/Cas9 Gene Editing in Hemophilia B 9:30 am
A landmark phase 1 clinical trial demonstrated successful gene editing for transthyretin amyloidosis, establishing proof of concept for CRISPR-Cas9 treatment in humans (Intellia Therapeutics and Regeneron Pharmaceuticals) Intellia Therapeutics and Regeneron Pharmaceuticals are developing a targeted insertion platform for the expression of Factor IX from the Albumin locus in liver for the treatment of Hemophilia…Read more
day: Day One